ronetics, Karus Therapeutics, Afferent, Calchan and Convergence, the latter three investments resulting from spin-outs from Roche (Afferent) and GSK (Calchan & Convergence), respectively. Prior to joining New Leaf, Liam previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as W